Skip to main content

Table 4 Responses and survival according to the risk scores

From: A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

Number of

Patients

ORR

mOS (95% CI)

mPFS (95% CI)

risk points

n (%)

%

months

months

0

7 (6.4%)

85.7%

not reached

not reached

1

19 (17.4%)

52.6%

22.2 (12.9–31.6)

6.2 (1.9–10.6)

2

21 (19.3%)

52.4%

29.7 (9.0-50.3)

6.6 (3.3–9.9)

3

29 (26.6%)

48.3%

20.9 (N/A)

5.2 (3.2–7.3)

4

18 (16.5%)

44.4%

10.0 (7.5–12.6)

4.2 (3.2–5.3)

5

12 (11.0%)

16.7%

8.4 (0.0-19.7)

2.0 (1.4–2.7)

6

3 (2.8%)

0%

2.0 (0.0-5.1)

1.6 (0.0-4.2)

  1. ORR, overall response rate; mOS, median overall survival; CI, confidence interval; mPFS, median progression-free survival; N/A, not available
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us